Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Membranous Glomerulonephritis | Phase 3 | CN | 02 Jun 2023 | |
Systemic Lupus Erythematosus | Phase 3 | CN | 26 May 2023 | |
Neuromyelitis Optica | Phase 3 | CN | 18 Aug 2022 | |
Refractory Follicular Lymphoma | Phase 3 | CN | 02 Jun 2021 | |
Marginal zone lymphoma refractory | Phase 2 | CN | 02 Jun 2021 | |
B-cell lymphoma recurrent | Phase 2 | CN | 28 Jul 2020 | |
B-cell lymphoma refractory | Phase 2 | CN | 28 Jul 2020 | |
CD20 positive B-Cell Lymphoma | Phase 2 | CN | 28 Jul 2020 | |
Refractory Indolent Non-Hodgkin Lymphoma | Phase 2 | CN | 28 Nov 2019 | |
Myasthenia Gravis | Phase 1 | CN | 27 Sep 2021 |
NCT05398653 (NEWS) Manual | Phase 1/2 | - | (ckyxriatbk) = honckpyhmy dfqumhtvgy (gnxkcrsieo ) View more | Positive | 23 Oct 2024 | ||
Cyclosporine | (ckyxriatbk) = wvmvtndnab dfqumhtvgy (gnxkcrsieo ) View more | ||||||
NCT04110301 (Pubmed) Manual | Phase 1/2 | 50 | (zigneohvki) = ekumpwuioe rwtumokkmt (tnwwcxbqbh, 73 - 94) View more | Positive | 01 Jul 2024 | ||
Phase 1/2 | 85 | (nfmmombklh) = occurred in 16.7%, 0.0% and 8.0% of patients in the MIL62 600 mg, MIL62 1000 mg and Cyclosporine group respectively srcunpzkli (grqpaclyrt ) View more | Positive | 14 Jun 2023 | |||
NCT04304040 (ASH2022) Manual | Phase 1/2 | 43 | (gmxrwjicmh) = mmzrefrreh pkmcvwxhim (bhzcdmkiqo ) View more | Positive | 12 Dec 2022 | ||
Phase 1/2 | 43 | gmsoelftsp(iuifagyrur) = MIL62输液反应发生率为11.6%, 均为 1-2级 tdkhpllkqj (ompvxyneqy ) View more | - | 21 Sep 2022 | |||
NCT04110301 (ASH2021) Manual | Phase 1/2 | 54 | (inlnzuxwgn) = dfttxasdpw tuxskufoqe (vojabikran ) View more | Positive | 05 Nov 2021 | ||
refractory to rituximab | (inlnzuxwgn) = mzkpvtscbv tuxskufoqe (vojabikran ) View more | ||||||
NCT04304040 (ESMO2021) Manual | Phase 1/2 | B-cell lymphoma refractory CD20 Positive | 14 | (wnxmideyfn) = thrombocytopenia (5/14, 35.7%), infusion-related reaction (3/14, 21.4%) and hyperuricemia (3/14, 21.4%) sspysbxevx (lyvtuoquun ) | Positive | 16 Sep 2021 | |
Phase 1 | 27 | (dlojnlrusk) = grade 1 infusion-related reaction was observed and experienced with 4 patients rtmhlgtspw (jihaoiuqbg ) View more | Positive | 17 Sep 2020 |